Darleukin/fibromun |
L19-IL-2/ L19-TNF-α |
Phase 3 Clinical |
Philogen Spa |
Carcinoma, Merkel Cell; Carcinoma, Basal Cell; Carcinoma, Skin Appendage; Keratoacanthoma; Basal Cell Nevus Syndrome; Carcinoma, Squamous Cell; Lymphoma, T-Cell, Cutaneous; Melanoma; Sarcoma, Kaposi |
Details
|
Bifikafusp alfa |
L19-IL-2 |
Phase 3 Clinical |
Philogen Spa |
Solid tumours; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis |
Details
|
BNZ-1 |
BNZ132-1-40; BNZ-1; BNZ132-1; BNZ-01; EQ101; EQ-101 |
Phase 2 Clinical |
Bioniz Therapeutics Inc |
Alopecia; Alopecia Areata; Lymphoma, T-Cell, Cutaneous; Leukemia, Large Granular Lymphocytic |
Details
|
umitrelimorgene autodencel |
ITI-1000 |
Phase 2 Clinical |
Immunomic Therapeutics Inc |
Glioblastoma |
Details
|
S-95007 |
S-95007 |
Phase 2 Clinical |
Laboratoires Servier |
Immune System Diseases; Inflammation |
Details
|
AU-007 |
BD-8; AU-007; BDG-8 |
Phase 2 Clinical |
Biolojic Design Inc |
Solid tumours; Neoplasms; Neoplasm Metastasis |
Details
|
XTX-202 |
XTX-202 |
Phase 2 Clinical |
Xilio Development Inc, Xilio Therapeutics Inc |
Solid tumours; Carcinoma, Renal Cell; Melanoma |
Details
|
LAT-010 |
LAT010; LAT-010 |
Phase 2 Clinical |
Latticon Antibody Therapeutics Inc |
Solid tumours |
Details
|
COYA-302 |
COYA302; COYA 302; COYA-302 |
Phase 2 Clinical |
Coya Therapeutics Inc |
Parkinson Disease; Frontotemporal Dementia; Amyotrophic Lateral Sclerosis |
Details
|
AVB-001 |
AVB-001 |
Phase 2 Clinical |
Avenge Bio Inc |
Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms |
Details
|
Saltikva |
|
Phase 2 Clinical |
Salspera LLC |
Pancreatic Neoplasms |
Details
|
LMBP2-specific TCR-T cell therapy (TCRCure Biopharma) |
|
Phase 2 Clinical |
Tcrcure Biopharma Ltd |
Nasopharyngeal Carcinoma |
Details
|
Interleukin-2 gene therapy (St Jude Children's Research Hospital) |
|
Phase 1 Clinical |
St Jude Children's Research Hospital, National Cancer Institute |
Neuroblastoma |
Details
|
T20K |
T-20K |
Phase 1 Clinical |
Cyxone |
Multiple Sclerosis |
Details
|
SIM-0278 |
ALM-223; SIM0278 |
Phase 1 Clinical |
Simcere Pharmaceutical Group Ltd |
Autoimmune Diseases; Lupus Erythematosus, Systemic; Dermatitis, Atopic |
Details
|
Mableukin 2PD1 (Anwita Biosciences) |
AWT020; AWT-020 |
Phase 1 Clinical |
Anwita Biosciences Inc |
Neoplasms; Autoimmune Diseases of the Nervous System |
Details
|
AB-248 |
AB-248 |
Phase 1 Clinical |
Asher Biotherapeutics Inc |
Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
ASP-1012 |
VET2-L2; ASP-1012; ASP1012 |
Phase 1 Clinical |
KaliVir Immunotherapeutics Inc |
Solid tumours |
Details
|
STK-012 |
STK-012 |
Phase 1 Clinical |
Synthekine Inc |
Solid tumours; Mismatch Repair Deficient Cancer; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Microsatellite instability-high cancer; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
IL2 CD25 fusion protein (Bristol-Myers Squibb) |
|
Phase 1 Clinical |
University Of Miami |
Autoimmune Diseases |
Details
|
M5A-IL2 Immunocytokine |
M5A-ICK |
Phase 1 Clinical |
National Cancer Institute, City Of Hope National Medical Center |
Breast Neoplasms; Colorectal Neoplasms |
Details
|
DF-6215 |
DF6215; DF-6215 |
Phase 1 Clinical |
Dragonfly Therapeutics Llc |
Solid tumours |
Details
|
Dodekin |
|
Phase 1 Clinical |
Philogen Spa |
Solid tumours; Neoplasm Metastasis |
Details
|
KB-707 |
KB-707; KB707 |
Phase 1 Clinical |
Krystal Biotech Inc |
Solid tumours; Skin Melanoma; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Neoplasms; Sarcoma; Osteosarcoma; Colorectal Neoplasms; Carcinoma, Squamous Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular |
Details
|
attIL2-T cell therapy |
|
Phase 1 Clinical |
The University Of Texas MD Anderson Cancer Center |
Soft Tissue Neoplasms; Osteosarcoma; Sarcoma |
Details
|
Autologous tumor-infiltrating lymphocyte cells therapy (Hervor Therapeutics) |
HV-101; HV101 |
Phase 1 Clinical |
Hervor Therapeutics, Tcrcure Biopharma Ltd, Hangzhou Houwu Biomedical Technology Co Ltd |
Solid tumours |
Details
|
KY-0118 |
KY-0118; KY0118 |
Phase 1 Clinical |
Novatim Immune Therapeutics (Zhejiang) Co Ltd |
Solid tumours; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
VIS171 |
VIS-171; VIS171 |
Phase 1 Clinical |
Visterra Inc |
Autoimmune Diseases |
Details
|
MK-1484 |
MK-1484; SP-482 |
Phase 1 Clinical |
Merck & Co Inc, Sutro Biopharma Inc |
Solid tumours |
Details
|
SAR-444336 |
SAR-444336 |
Phase 1 Clinical |
Sanofi |
Inflammation |
Details
|
RS-2102 |
RS2102 |
Phase 1 Clinical |
Reistone Biopharma Co Ltd |
Dermatitis, Atopic |
Details
|
RG-6279 |
RG-6279 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Solid tumours |
Details
|
BNT-153 |
BNT-153 |
Phase 1 Clinical |
Biontech Se |
Solid tumours |
Details
|
Igrelimogene litadenorepvec |
PM-1016; PM1016; TILT-123 |
Phase 1 Clinical |
Tilt Biotherapeutics Ltd |
Solid tumours; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Peritoneal Neoplasms; Lung Neoplasms; Fallopian Tube Neoplasms; Melanoma; Carcinoma, Hepatocellular |
Details
|
Darleukin/fibromun |
L19-IL-2/ L19-TNF-α |
Phase 3 Clinical |
Philogen Spa |
Carcinoma, Merkel Cell; Carcinoma, Basal Cell; Carcinoma, Skin Appendage; Keratoacanthoma; Basal Cell Nevus Syndrome; Carcinoma, Squamous Cell; Lymphoma, T-Cell, Cutaneous; Melanoma; Sarcoma, Kaposi |
Details
|
Bifikafusp alfa |
L19-IL-2 |
Phase 3 Clinical |
Philogen Spa |
Solid tumours; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis |
Details
|
BNZ-1 |
BNZ132-1-40; BNZ-1; BNZ132-1; BNZ-01; EQ101; EQ-101 |
Phase 2 Clinical |
Bioniz Therapeutics Inc |
Alopecia; Alopecia Areata; Lymphoma, T-Cell, Cutaneous; Leukemia, Large Granular Lymphocytic |
Details
|
umitrelimorgene autodencel |
ITI-1000 |
Phase 2 Clinical |
Immunomic Therapeutics Inc |
Glioblastoma |
Details
|
S-95007 |
S-95007 |
Phase 2 Clinical |
Laboratoires Servier |
Immune System Diseases; Inflammation |
Details
|
AU-007 |
BD-8; AU-007; BDG-8 |
Phase 2 Clinical |
Biolojic Design Inc |
Solid tumours; Neoplasms; Neoplasm Metastasis |
Details
|
XTX-202 |
XTX-202 |
Phase 2 Clinical |
Xilio Development Inc, Xilio Therapeutics Inc |
Solid tumours; Carcinoma, Renal Cell; Melanoma |
Details
|
LAT-010 |
LAT010; LAT-010 |
Phase 2 Clinical |
Latticon Antibody Therapeutics Inc |
Solid tumours |
Details
|
COYA-302 |
COYA302; COYA 302; COYA-302 |
Phase 2 Clinical |
Coya Therapeutics Inc |
Parkinson Disease; Frontotemporal Dementia; Amyotrophic Lateral Sclerosis |
Details
|
AVB-001 |
AVB-001 |
Phase 2 Clinical |
Avenge Bio Inc |
Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms |
Details
|
Saltikva |
|
Phase 2 Clinical |
Salspera LLC |
Pancreatic Neoplasms |
Details
|
LMBP2-specific TCR-T cell therapy (TCRCure Biopharma) |
|
Phase 2 Clinical |
Tcrcure Biopharma Ltd |
Nasopharyngeal Carcinoma |
Details
|
Interleukin-2 gene therapy (St Jude Children's Research Hospital) |
|
Phase 1 Clinical |
St Jude Children's Research Hospital, National Cancer Institute |
Neuroblastoma |
Details
|
T20K |
T-20K |
Phase 1 Clinical |
Cyxone |
Multiple Sclerosis |
Details
|
SIM-0278 |
ALM-223; SIM0278 |
Phase 1 Clinical |
Simcere Pharmaceutical Group Ltd |
Autoimmune Diseases; Lupus Erythematosus, Systemic; Dermatitis, Atopic |
Details
|
Mableukin 2PD1 (Anwita Biosciences) |
AWT020; AWT-020 |
Phase 1 Clinical |
Anwita Biosciences Inc |
Neoplasms; Autoimmune Diseases of the Nervous System |
Details
|
AB-248 |
AB-248 |
Phase 1 Clinical |
Asher Biotherapeutics Inc |
Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
ASP-1012 |
VET2-L2; ASP-1012; ASP1012 |
Phase 1 Clinical |
KaliVir Immunotherapeutics Inc |
Solid tumours |
Details
|
STK-012 |
STK-012 |
Phase 1 Clinical |
Synthekine Inc |
Solid tumours; Mismatch Repair Deficient Cancer; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Microsatellite instability-high cancer; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
IL2 CD25 fusion protein (Bristol-Myers Squibb) |
|
Phase 1 Clinical |
University Of Miami |
Autoimmune Diseases |
Details
|
M5A-IL2 Immunocytokine |
M5A-ICK |
Phase 1 Clinical |
National Cancer Institute, City Of Hope National Medical Center |
Breast Neoplasms; Colorectal Neoplasms |
Details
|
DF-6215 |
DF6215; DF-6215 |
Phase 1 Clinical |
Dragonfly Therapeutics Llc |
Solid tumours |
Details
|
Dodekin |
|
Phase 1 Clinical |
Philogen Spa |
Solid tumours; Neoplasm Metastasis |
Details
|
KB-707 |
KB-707; KB707 |
Phase 1 Clinical |
Krystal Biotech Inc |
Solid tumours; Skin Melanoma; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Neoplasms; Sarcoma; Osteosarcoma; Colorectal Neoplasms; Carcinoma, Squamous Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular |
Details
|
attIL2-T cell therapy |
|
Phase 1 Clinical |
The University Of Texas MD Anderson Cancer Center |
Soft Tissue Neoplasms; Osteosarcoma; Sarcoma |
Details
|
Autologous tumor-infiltrating lymphocyte cells therapy (Hervor Therapeutics) |
HV-101; HV101 |
Phase 1 Clinical |
Hervor Therapeutics, Tcrcure Biopharma Ltd, Hangzhou Houwu Biomedical Technology Co Ltd |
Solid tumours |
Details
|
KY-0118 |
KY-0118; KY0118 |
Phase 1 Clinical |
Novatim Immune Therapeutics (Zhejiang) Co Ltd |
Solid tumours; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
VIS171 |
VIS-171; VIS171 |
Phase 1 Clinical |
Visterra Inc |
Autoimmune Diseases |
Details
|
MK-1484 |
MK-1484; SP-482 |
Phase 1 Clinical |
Merck & Co Inc, Sutro Biopharma Inc |
Solid tumours |
Details
|
SAR-444336 |
SAR-444336 |
Phase 1 Clinical |
Sanofi |
Inflammation |
Details
|
RS-2102 |
RS2102 |
Phase 1 Clinical |
Reistone Biopharma Co Ltd |
Dermatitis, Atopic |
Details
|
RG-6279 |
RG-6279 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Solid tumours |
Details
|
BNT-153 |
BNT-153 |
Phase 1 Clinical |
Biontech Se |
Solid tumours |
Details
|
Igrelimogene litadenorepvec |
PM-1016; PM1016; TILT-123 |
Phase 1 Clinical |
Tilt Biotherapeutics Ltd |
Solid tumours; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Peritoneal Neoplasms; Lung Neoplasms; Fallopian Tube Neoplasms; Melanoma; Carcinoma, Hepatocellular |
Details
|